title: [European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. Spanish adaptation of the CEIPC 2008].
abstract: We present the Spanish adaptation made by the CEIPC of the European Guidelines on Cardiovascular Disease Prevention (CVD) in Clinical Practice 2008. This guide recommends the SCORE model for risk evaluation. The aim is to prevent premature mortality and morbidity due to CVD through the management of its related risk factors in clinical practice. The guide focuses on primary prevention and emphasizes the role of the nurses and primary care medical doctors in promoting a healthy life style, based on increasing physical activity, change dietary habits, and non smoking. The therapeutic goal is to achieve a Blood Pressure < 140/90 mmHg, but among patients with diabetes, chronic kidney disease, or definite CVD, the objective is <130/80 mmHg. Serum cholesterol should be < 200 mg/dl and cLDL<130 mg/dl, although among patients with CVD or diabetes, the objective is <100 mg/dl (80 mg/dl if feasible in very high-risk patients). Patients with type 2 diabetes and those with metabolic syndrome must lose weight and increase their physical activity, and drugs must be administered whenever applicable, to reach body mass index (BMI) guided and waist circumference objectives. In diabetic type 2 patients, the objective is glycated haemoglobin <7%. Allowing people to know the guides and developing implementation programs, identifying barriers and seeking solutions for them, are priorities for the CEIPC in order to transfer the recommendations established into the daily clinical practice.
authors.affiliation: Sociedad Española de Medicina de Familia y Comunitaria. jmlobos@telefonica.net
authors.forename: J M
authors.initials: JM
authors.lastname: Lobos
authors.forename: M A
authors.initials: MA
authors.lastname: Royo-Bordonada
authors.forename: C
authors.initials: C
authors.lastname: Brotons
authors.forename: L
authors.initials: L
authors.lastname: Alvarez-Sala
authors.forename: P
authors.initials: P
authors.lastname: Armario
authors.forename: A
authors.initials: A
authors.lastname: Maiques
authors.forename: D
authors.initials: D
authors.lastname: Mauricio
authors.forename: S
authors.initials: S
authors.lastname: Sans
authors.forename: F
authors.initials: F
authors.lastname: Villar
authors.forename: A
authors.initials: A
authors.lastname: Lizcano
authors.forename: A
authors.initials: A
authors.lastname: Gil-Núñez
authors.forename: F
authors.initials: F
authors.lastname: de Alvaro
authors.forename: P
authors.initials: P
authors.lastname: Conthe
authors.forename: E
authors.initials: E
authors.lastname: Luengo
authors.forename: A
authors.initials: A
authors.lastname: del Río
authors.forename: O
authors.initials: O
authors.lastname: Rico
authors.forename: A
authors.initials: A
authors.lastname: de Santiago
authors.forename: M A
authors.initials: MA
authors.lastname: Vargas
authors.forename: M
authors.initials: M
authors.lastname: Martíonez
authors.forename: V
authors.initials: V
authors.lastname: Lizarbe
mesh_terms: D000367:Age Factors; D015415:Biomarkers; D001794:Blood Pressure; D015992:Body Mass Index; D002318:Cardiovascular Diseases / Q000401:mortality / Q000503:physiopathology / Q000517:prevention & control* / Q000628:therapy; D002784:Cholesterol / Q000097:blood; D015510:Clinical Medicine / Q000592:standards*; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000517:prevention & control; D006801:Humans; D008019:Life Style; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D010818:Practice Patterns, Physicians'; D012307:Risk Factors; D013030:Spain
chemical_list: D015415:Biomarkers; D010975:Platelet Aggregation Inhibitors; D002784:Cholesterol